Growth‐inhibitory effects of combination chemotherapy for human pancreatic cancer cell lines

Seiki Matsuno, Hirotake Hisano, Masao Kobari, Satoshi Akaishi

Research output: Contribution to journalArticlepeer-review

19 Citations (Scopus)


Sensitivities to anti‐tumor drugs, mytomycin C (MMC), aclarubicin hydrochloride (ACR), doxorubicin hydrochloride (ADR), cisplatin, and 5‐fluorouracil (5FU), were examined using PK‐1, ‐8, ‐9, ‐12, ‐14, and ‐16 cell lines derived from human pancreatic cancer. These cell lines showed different sensitivities to each of the above anti‐tumor drugs. the concentrations required for 50% growth‐inhibition (IC50) after 2 hours of exposure were 0.096 to 0.35 μg/ml for MMC, 0.0074 to 0.0076 μg/ml for ACR, 0.033 to 0.23 μg/ml for ADR, 0.35 to 1.9 μg/ml for cisplatin, and 21 to 42 μg/ml for 5FU. IC50 of each anti‐tumor drug decreased significantly after 48 hours of exposure. the combination of any two out of MMC, ACR, and 5FU showed synergistic inhibition of the growth of PK‐1 and PK‐8 cell lines. These results show that MMC, ACR, ADR, cisplatin, and 5FU have sufficient anti‐tumor effect against six human pancreatic cancer cell lines even at clinically achievable concentrations and exposure times, and chemotherapy for pancreatic cancers requires naturally effective drug delivery into cancer tissues.

Original languageEnglish
Pages (from-to)2369-2374
Number of pages6
Issue number11
Publication statusPublished - 1990 Dec 1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Growth‐inhibitory effects of combination chemotherapy for human pancreatic cancer cell lines'. Together they form a unique fingerprint.

Cite this